Evommune, Inc. income statement

In fiscal 2025, Evommune, Inc. reported revenue of $13.0m, up 85.7% on the year before, operating income of −$81.1m (a -623.6% margin) and net income of −$68.9m, or −$11.22 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Evommune, Inc.: income statement, annual
Fiscal year	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	7	13	10
Research and development	64	74	84
General and administrative	13	20	28
Operating income	−70	−81	−102
Income before tax	−68	−69	—
Income tax	0	0	0
Net income	−67	−69	−95
Diluted EPS	−$11.32	−$11.22	—
Diluted shares (average)	6m	6m	—
EBITDA	−70	−80	−101

US$ millions unless shown otherwise. Fiscal quarters.

Evommune, Inc.: income statement, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	0	3	0	10	0	0	0
Research and development	18	14	20	20	20	17	26
General and administrative	4	4	3	4	9	7	8
Operating income	−21	−15	−23	−13	−30	−24	−35
Income tax	0	0	0	0	0	0	0
Net income	−21	−15	−14	−12	−28	−22	−32
Diluted EPS	−$14.60	−$9.48	−$8.80	−$8.07	$15.14	−$0.64	−$0.89
EBITDA	−22	−15	−23	−13	−30	−24	−35

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CRBU vs EVMN EVMN vs IRD EVMN vs RLAY

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Evommune, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Evommune, Inc.